keyword
https://read.qxmd.com/read/38610117/the-personal-impact-of-living-with-a-myeloproliferative-neoplasm
#1
JOURNAL ARTICLE
A A M Eppingbroek, L Lechner, E C Bakker, M D Nijkamp, M A de Witte, C A W Bolman
OBJECTIVE: The aim of this study is to gain insight into the physical, psychological and social impact of having a myeloproliferative neoplasm (MPN), a rare type of cancer with an often chronic course. METHODS: An online survey was conducted among 455 Dutch MPN patients (62.7% female, age M 63) to explore the impact of the disease by measuring the MPN symptom burden (MPN-SAF TSS) and quality of life (QoL) (EORTC QLQ-C30) and its subscales within a hierarchical QoL model...
April 2024: Psycho-oncology
https://read.qxmd.com/read/38606222/a-review-about-the-assessment-of-the-bleeding-and-thrombosis-risk-for-patients-with-myeloproliferative-neoplasms-scheduled-for-surgery
#2
REVIEW
Mihaela Andreescu, Bogdan Andreescu
Myeloproliferative neoplasms (MPNs) present a unique challenge in surgical management due to their inherent predisposition to both bleeding and thrombosis. MPNs are a heterogenous group of acquired clonal conditions. The three classic MPNs are essential thrombocythemia (ET), myelofibrosis (PMF), and polycythemia vera (PV). All subtypes of MPN are associated with both thrombotic and bleeding complications. There are four risk categories for thrombosis in MPN patients: age, thrombosis history, and JAK -2 mutation...
March 2024: Curēus
https://read.qxmd.com/read/38566064/successful-management-of-vte-with-essential-thrombocythemia-and-cavernous-transformation-of-the-portal-vein-in-early-pregnancy-a-case-report
#3
JOURNAL ARTICLE
Xin Kang, Shibin Hong, Chengxi Tan, Wen Di, Ning Zhang
Due to the thrombohemorrhagic potential of essential thrombocythemia, pregnancy complicated by essential thrombocythemia should be recognized as a risk factor for obstetric complications. Here, we report the case of a patient with essential thrombocythemia with two significantly different pregnancy outcomes. Her first pregnancy (at 30 years of age) ended with an uneventful term delivery. However, the patient progressed to cavernous transformation of the portal vein in the period between her two pregnancies and subsequently experienced deep venous thrombosis during the first trimester of her second pregnancy (at 36 years of age)...
April 2, 2024: BMC Women's Health
https://read.qxmd.com/read/38512218/merkel-cell-carcinoma-on-the-face-a-case-report
#4
JOURNAL ARTICLE
Shaikha Salah Alhaj, Fatma Abdulghaffar Qaderi, Tarek Ibrahim, Maha Almohammad
Background: Merkel cell carcinoma (MCC) is a rare primary neuroendocrine skin tumor that represents a flesh-colored or bluish-red nodule on the face, neck, or head. Long-term Ultraviolet (UV) radiation exposure and Merkel cell polyomavirus (MCV) are associated with Merkel cell carcinoma pathogenesis. We present a case of Merkel cell carcinoma in an 87-year-old male patient in the right cheek. Objective: The primary goal of presenting the case was to bring Merkel cell carcinoma, which is a diagnostic challenge, to the notice of dermatologists and oncologists, as early detection and prompt treatment are important...
March 17, 2024: JMIR dermatology
https://read.qxmd.com/read/38455691/a-case-of-acute-myocardial-infarction-in-a-patient-with-essential-thrombocythaemia-treated-with-anagrelide
#5
JOURNAL ARTICLE
Ekrem Yetiskul, Aqsa Nisar, Salman Khan, Faris Qaqish, Danyal Khan, Alexander Bershadskiy
UNLABELLED: Anagrelide is a medication primarily used to manage thrombocytosis, an abnormal increase in platelet levels in the blood. It is often prescribed for patients with myeloproliferative disorders, such as essential thrombocythaemia (ET). Given the heightened susceptibility to thromboembolism associated with this condition, the primary emphasis in treatment revolves around reducing the risk of thrombotic events through the administration of cytotoxic agents. While anagrelide is generally effective in reducing platelet counts, it comes with potential side effects, including an increased risk of certain thrombotic events...
2024: European Journal of Case Reports in Internal Medicine
https://read.qxmd.com/read/38454387/retinochoroiditis-secondary-to-rickettsia-typhi-infection-a-case-report
#6
JOURNAL ARTICLE
Joanne Makhoul, Yael Ben-Arie-Weintrob, Dror Ben Ephraim Noyman
BACKGROUND: To report a case of unusual presentation of retinochoroiditis caused by Rickettsia typhi in a patient without prior uveitis. CASE PRESENTATION: In this case, we describe a 24-year-old male soldier with no previous eye disease, who was referred to our ophthalmology department due to bilateral retinochoroiditis and vitritis. The patient initially presented with a paracentral scotoma in his right eye persisting for 7 days and scattered dark spots in his left eye for 2 days in June 2023...
March 7, 2024: BMC Ophthalmology
https://read.qxmd.com/read/38440831/shp2-inhibition-displays-efficacy-as-a-monotherapy-and-in-combination-with-jak2-inhibition-in-preclinical-models-of-myeloproliferative-neoplasms
#7
JOURNAL ARTICLE
Garima Pandey, Lucia Mazzacurati, Tegan M Rowsell, Nathan P Horvat, Narmin E Amin, Guolin Zhang, Afua A Akuffo, Christelle M Colin-Leitzinger, Eric B Haura, Andrew T Kuykendall, Ling Zhang, Pearlie K Epling-Burnette, Gary W Reuther
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocytosis, and primary myelofibrosis, are clonal hematopoietic neoplasms driven by mutationally activated signaling by the JAK2 tyrosine kinase. Although JAK2 inhibitors can improve MPN patients' quality of life, they do not induce complete remission as disease-driving cells persistently survive therapy. ERK activation has been highlighted as contributing to JAK2 inhibitor persistent cell survival. As ERK is a component of signaling by activated RAS proteins and by JAK2 activation, we sought to inhibit RAS activation to enhance responses to JAK2 inhibition in preclinical MPN models...
March 5, 2024: American Journal of Hematology
https://read.qxmd.com/read/38375212/an-approach-to-the-investigation-of-thrombocytosis-differentiating-between-essential-thrombocythemia-and-secondary-thrombocytosis
#8
JOURNAL ARTICLE
Ala Almanaseer, Benjamin Chin-Yee, Jenny Ho, Alejandro Lazo-Langner, Laila Schenkel, Pratibha Bhai, Bekim Sadikovic, Ian H Chin-Yee, Cyrus C Hsia
BACKGROUND: Thrombocytosis is a common reason for referral to Hematology. Differentiating between secondary causes of thrombocytosis and essential thrombocythemia (ET) is often clinically challenging. A practical diagnostic approach to identify secondary thrombocytosis could reduce overinvestigation such as next generation sequencing (NGS) panel. METHODS AND RESULTS: All adult patients with thrombocytosis (≥450 × 109 /L) who underwent molecular testing at a single tertiary care centre between January 1, 2018 and May 31, 2021 were evaluated...
2024: Advances in Hematology
https://read.qxmd.com/read/38361779/case-report-peri-procedural-hydroxyurea-helps-minimize-bleeding-in-patients-with-essential-thrombocythemia-associated-with-acquired-von-willebrand-syndrome
#9
Leah Kogan, Russell Price, Rouslan Kotchetkov
BACKGROUND: Essential Thrombocythemia is a chronic myeloproliferative neoplasm characterized by an isolated excessive production of platelets. Extreme thrombocytosis is defined by having a platelet count greater than or equal to 1,000 x 109 /L, which may lead to the development of acquired von Willebrand syndrome and complications of excessive hemorrhage. CASE DESCRIPTION: A 74-year-old female patient was brought in for a bone marrow examination regarding elevated platelet count...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38356903/homozygous-sickle-cell-disease-after-age-of-40-follow-up-of-a-cohort-of-209-patients-in-senegal-west-africa
#10
JOURNAL ARTICLE
Moussa Seck, Maureen Adéniké Dabo, Elimane Seydi Bousso, Mohamed Keita, Sokhna Aïssatou Touré, Sérigne Mourtalla Guèye, Blaise Félix Faye, Fatma Dieng, Saliou Diop
OBJECTIVES: The aim of this study was to describe the morbidity and mortality of homozygous sickle cell disease after the age of 40. METHODS: This was a cohort study of 209 patients followed from 1994 to 2022. All hemoglobin electrophoresis-confirmed SS sickle cell patients over 40 years were included. A descriptive study of epidemiological, diagnostic, therapeutic, and evolutionary data was used to assess morbidity and mortality. RESULTS: Sex ratio (M/F) was 0...
2024: Advances in Hematology
https://read.qxmd.com/read/38338695/red-blood-cell-contribution-to-thrombosis-in-polycythemia-vera-and-essential-thrombocythemia
#11
REVIEW
Julien M P Grenier, Wassim El Nemer, Maria De Grandis
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) characterized by clonal erythrocytosis and thrombocytosis, respectively. The main goal of therapy in PV and ET is to prevent thrombohemorrhagic complications. Despite a debated notion that red blood cells (RBCs) play a passive and minor role in thrombosis, there has been increasing evidence over the past decades that RBCs may play a biological and clinical role in PV and ET pathophysiology. This review summarizes the main mechanisms that suggest the involvement of PV and ET RBCs in thrombosis, including quantitative and qualitative RBC abnormalities reported in these pathologies...
January 24, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38333237/digital-gangrene-can-be-the-first-manifestation-of-essential-thrombocythemia-a-case-report
#12
Amirhossein Mirhosseini, Ramin Bozorgmehr, Fatemeh Bastan, Maryam Rashidian
INTRODUCTION AND IMPORTANCE: Essential thrombocythemia (ET) is a rare chronic myeloproliferative hematologic disorder, leading to an elevated platelet count. Two-thirds of patients are asymptomatic during their lifetime, while others may experience symptoms like redness, congestion, and erythromelalgia after long symptom-free intervals. CASE PRESENTATION: The authors present a rare instance of a 55-year-old female who, despite receiving aspirin and losartan treatment, eventually developed digital gangrene...
February 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38269572/essential-thrombocythemia-2024-update-on-diagnosis-risk-stratification-and-management
#13
JOURNAL ARTICLE
Ayalew Tefferi, Alessandro Maria Vannucchi, Tiziano Barbui
OVERVIEW: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microcirculatory symptoms (e.g., headaches, lightheadedness, and acral paresthesias), and, less frequently, by disease transformation into myelofibrosis (MF) or acute myeloid leukemia. DIAGNOSIS: In addition to thrombocytosis (platelets ≥450 × 109 /L), formal diagnosis requires the exclusion of other myeloid neoplasms, including prefibrotic MF, polycythemia vera, chronic myeloid leukemia, and myelodysplastic syndromes with ring sideroblasts and thrombocytosis...
January 25, 2024: American Journal of Hematology
https://read.qxmd.com/read/38238303/one-thousand-patients-with-essential-thrombocythemia-the-mayo-clinic-experience
#14
JOURNAL ARTICLE
Naseema Gangat, Omer Karrar, Aref Al-Kali, Kebede H Begna, Michelle A Elliott, Alexandra P Wolanskyj-Spinner, Animesh Pardanani, Curtis A Hanson, Rhett P Ketterling, Ayalew Tefferi
We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between 1967 and 2023: median age 58 years (18-90), females 63%, JAK2/CALR/MPL-mutated 62%/27%/3%, triple-negative (TN) 8%, extreme thrombocytosis (ExT; platelets ≥1000 × 109 /L) 26%, leukocytosis (leukocyte count >11 × 109 /L) 20%, and abnormal karyotype 6%. JAK2-mutated patients were older (median 71 years), and CALR mutated (52 years), and TN (50 years) younger (p < 0...
January 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38238287/one-thousand-patients-with-essential-thrombocythemia-the-florence-crimm-experience
#15
JOURNAL ARTICLE
Giuseppe G Loscocco, Francesca Gesullo, Giulio Capecchi, Alessandro Atanasio, Chiara Maccari, Francesco Mannelli, Alessandro M Vannucchi, Paola Guglielmelli
We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18-95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets ≥1000 × 109 /L) in 16%, leukocytosis (leukocytes >11 × 109 /L) in 16%, and at least one cardiovascular risk factor in 52% of cases. JAK2-mutated patients were older (median 62 years) and CALR-mutated and TN (53 years for both) younger (p < 0...
January 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38229794/a-case-of-jak2v617f-negative-myeloproliferative-neoplasm-in-a-young-female-presenting-with-extreme-thrombocytosis
#16
Kelash Kumar, Assile Koubeissy, Arichanah Pulenthiran, Amrat Kumar, Amit Gulati, Brian Wolf, Stephen Peeke
Thrombocytosis is a commonly observed condition in clinical practice and typically results from various pathophysiological factors, such as iron deficiency, blood loss, infection, medications, rheumatologic conditions, malignancy, asplenia, post-splenectomy, or familial factors. However, extreme thrombocytosis, defined as a platelet count > 10,000 K/UL (equal or greater than a million), is a rare occurrence. In this report, we present a compelling case of severe thrombocytosis attributed to underlying chronic myelogenous leukemia (CML), further complicated by coexisting iron deficiency...
December 2023: Curēus
https://read.qxmd.com/read/38203347/aberrant-platelet-aggregation-as-initial-presentation-of-essential-thrombocythemia-failure-of-entero-coated-aspirin-to-reduce-platelet-hyperactivation
#17
Alessandro Morotti, Cristina Barale, Michele Sornatale, Emilia Giugliano, Vittorio Emanuele Muccio, Chiara Frascaroli, Marisa Pautasso, Alessandro Fornari, Isabella Russo
Essential thrombocythemia (ET) is a myeloproliferative neoplasm variant characterized by excessive production of platelets. Since the most common cause of mortality and morbidity in ET patients is thrombosis, the excessive production of platelets may cause thrombotic events. However, little is known about the function of platelets in ET. We report a female patient who presented as asymptomatic, without a remarkable medical history, and ET was diagnosed after an incidental finding of moderate thrombocytosis...
December 22, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38090964/splanchnic-venous-thrombosis-and-recurrent-spontaneous-abortion-due-to-latent-essential-thrombocytosis-revealed-after-20-years-case-report
#18
JOURNAL ARTICLE
Mansoor C Abdulla
A 50-year old housewife presented to our department with recurrent pain and bluish discoloration of bilateral lateral two toes for 1 year. She had multiple thrombotic complications (portal vein thrombosis, small bowel ischemia, and recurrent abortions) at the age of 30 years for which a cause was not identified. She had a long asymptomatic period of 20 years following that and was diagnosed to have essential thrombocytosis (ET) when she was admitted with digital ischemia. She was started on hydroxyurea and aspirin...
June 22, 2023: Indian Journal of Cancer
https://read.qxmd.com/read/38063345/stability-of-potassium-calcium-and-phosphorus-electrolytes-in-three-different-tubes-in-patients-with-essential-thrombocytosis
#19
JOURNAL ARTICLE
Murat Aksit, Merve Zeytinli Aksit, Ayfer Colak, Banu Isbilen Basok, Cengiz Ceylan
Proper blood collection and timely analysis are vital steps for reliable results. This study aims to compare potassium(K), calcium(Ca), and phosphorus(P) concentrations in serum separator tube (SST), lithium heparin tube without gel (LiH), and lithium heparin tube with a barrier (Barricor)tubes in essential thrombocytosis(ET) patients. Additionally, we assessed short-term stability of these analytes at room temperature. K, Ca and P concentrations of blood taken from 40 ET patients into SST, LiH and Barricor tubes were measured at 0, 2, 4 and 8 h...
December 2023: Scandinavian Journal of Clinical and Laboratory Investigation
https://read.qxmd.com/read/38022049/atypical-kawasaki-disease-presentation-in-a-previously-healthy-infant-a-diagnostic-challenge
#20
Ali Aizad Raza, Warisha Khan, Arshan A Khan, Syed Kanza Mahrukh, Krishnan Balasubramanian
Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children, characterized by fever and multisystem involvement. We present a compelling case of KD in a previously healthy 13-week-old infant who presented with fever, irritability, reduced feeding, and the subsequent development of classical mucocutaneous manifestations, including bilateral non-purulent conjunctivitis, cracked lips, and an erythematous rash. Laboratory findings revealed elevated inflammatory markers, thrombocytosis, and neutrophilic leukocytosis, consistent with the diagnosis...
October 2023: Curēus
keyword
keyword
25398
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.